Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L22 pseudogene 18 (RPL22P18) is a processed pseudogene in the human genome that shares sequence similarity with the functional ribosomal protein L22 gene (RPL22)[2][7][8]. Pseudogenes like RPL22P18 arise through retrotransposition or gene duplication events but have lost the ability to encode a functional protein due to mutations such as premature stop codons or frameshifts[2]. As a pseudogene, RPL22P18 is not involved in protein synthesis and is not considered a drug target or therapeutic receptor. While its parent gene RPL22 is important for ribosomal structure and function, the pseudogene has no known biological activity or disease relevance[2][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L22 pseudogene 18 (RPL22P18).